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doi:10.1016/j.ejvs.2011.05.018Abstract Objective: The study aimed to analyse and report the results of a ‘local anaes-
thesia first’ approach in elective endovascular aneurysm repair (EVAR) patients.
Material and methods: Between January 2007 and August 2010, a total of 217 continuous
patients (187 men, median age 76 years, range 52e94 years) underwent elective EVAR using
this approach, with predefined exclusion criteria for local anaesthesia (LA). A retrospective
analysis regarding technical feasibility, mortality, complication and endoleak rate was per-
formed. The results are reported as an observational study.
Results: LA was applied in 183 patients (84%), regional anaesthesia (RA) in nine patients (4%)
and general anaesthesia (GA) in 25 patients (12%). Anaesthetic conversion from LA to GA
was necessary in 14 patients (7.6%). Airway obstruction (n Z 4) and persistent coughing
(n Z 3) were the most common causes for conversion to GA. Thirty-day mortality in the LA
group was 2.7%, with 16/183 patients (8.7%) experiencing postoperative complications. All
type I endoleaks (nZ 5, 2.7%) occurred in patients with LA and challenging aneurysm morphol-
ogies.
Conclusions: A ‘local anaesthesia first’ strategy can successfully be applied in 75% of patients
undergoing EVAR. The use of LA can impact imaging quality and thus precise endograft place-
ment, which should be considered in patients with challenging aneurysm morphologies.
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Table 1 Contraindications for local anesthesia (n Z 34).
Absolute Contraindications Relative Contraindications
History of difficult airway management (n Z 5) Obesity (BMI > 35 kg/m2) (n Z 6)
Patients choice (n Z 12) Sleep Apnoea (n Z 4)
Retroperitoneal approach (n Z 1) Surgeon’s preference (n Z 2)
Previous groin surgery (n Z 4)
Severe gastro esophageal reflux
Anxiety
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Endovascular aortic repair (EVAR) has become the first-line
treatment option for patients with infrarenal aortic aneu-
rysms.1,2 In addition to its surgically ‘minimal invasive
approach’, this treatment modality offers the opportunity
of using local (LA) or regional anaesthesia (RA) to poten-
tially further decrease perioperative morbidity and
mortality, especially in patients with high significant co-
morbidities.3e5 Although feasibility and safety of LA in EVAR
has been proven, it still has not become accepted on a large
scale as a first-line anaesthetic option and is only applied in
a small percentage of EVAR patients (5e10%).5e10 Reasons
include the possibility for optimised imaging and exact
placement of the graft, a traditional surgical attitude
preferring general anaesthesia (GA) or the fear for either
emergency anaesthetic (LA to GA) or surgical conversion
(EVAR to open repair) due to intra-operative complications.
The recently published practice guidelines of the Society
of Vascular Surgery categorise the level of recommendation
and evidence for the use of RA or LA for EVAR as weak or
low, respectively.11 The aim of this study was therefore to
report and analyse the results of a unified, ‘local anaes-
thesia first’ strategy in a large, prospective and continuous
patient cohort of a high-volume EVAR centre.Table 2 Baseline characteristics of all patients undergoing EVA
LA (n Z 183)
Age (yrs) 76 (54e94)
Sex (male) 157 (86)
BMI (kg/m2) 27 (16e38)
ASA score
I e
II 6 (3)
III 148 (81)
IV 29 (16)
SVS-AAVS Medical co-morbidity grading system12
- Cardiac risk level 2 107 (58)
- Renal risk level 2 8 (4)
- Pulmonary risk level 2 33 (18)
History of smoking 154 (84)
Diabetes 34 (19)
Hyperlipidaemia 147 (80)
Hypertension 160 (87)
COPD 56 (31)
Sleep Apnoea 10 (5)
Preoperative Anticoagulation 131 (72)
LA: Local anesthesia, RA: Regional anesthesia, GA: General anesthesia
Vascular Surgery ASA: American Society of Anesthesiologists, BMI: boMethodsPatient population
Between March 1994 and August 2010, endovascular aortic
repair of an infrarenal aortic aneurysm was performed in
958 patients. In January 2007, as a result of an institutional
commitment to less invasive approaches, we changed our
anaesthesia strategy, using LA with monitored anaesthesia
care in all patients, while reserving RA defined as spinal or
epidural anaesthesia and GA for patients with predefined
contraindications (Table 1). Between January 2007 and
August 2010, 217 continuous patients (187 men, median age
76 years, range 52e94 years) underwent elective EVAR with
this anaesthetic strategy. LA was used in 183 patients (84%),
RA in nine patients (4%) and GA in 25 patients (12%).
Patients with symptomatic/ruptured aortic aneurysms, re-
interventions after previous EVAR and patients requiring
fenestrated stent grafts were excluded from this analysis.
For preoperative risk stratification, the patients were
scored using the American Society of Anesthesiologists
(ASA) classification and the medical co-morbidity grading
system suggested by the Ad Hoc Committee for Standard-
ized Reporting Practices in Vascular Surgery of the SocietyR (n Z 217).
RA (n Z 9) GA (n Z 25)
72 (63e79) 73 (52e85)
6 (67) 24 (96)
26 (17e31) 27 (19e50)
e e
e e
6 (67) 16 (64)
3 (33) 9 (36)
6 (67) 14 (56)
2 (22) 2 (8)
3 (33) 4 (16)
7 (77) 22 (88)
2 (22) 7 (28)
5 (55) 19 (76)
8 (89) 22 (88)
5 (55) 10 (40)
1 (11) 3 (12)
7 (77) 18 (72)
SVS-AAVS: Society for Vascular Surgery/American Association for
dy mass index, COPD: chronic obstructive pulmonary disease.
LA in EVAR 469for Vascular Surgery/American Association for Vascular
Surgery.12 This medical co-morbidity grading system is
a score that involves age and cardiac-, pulmonary- and
renal-related risk factors (Level 0/1 Z low/minimal risk to
Level 2/3 Z moderate/high-risk level). Baseline charac-
teristics of the patients are presented in Table 2.
Procedure
All procedures were performed with a team involving
vascular surgeons, interventional radiologists and anaes-
thesiologists in an angiography setting.13 The following
stent grafts were used: Talent (Medtronic, Santa Rosa, CA,
USA; n Z 41), Excluder (W.L. Gore & Associates, Flagstaff,
AZ, USA; n Z 130), Aneurx (Medtronic; n Z 7), Zenith
(Cook, Bloomington, IL, USA; n Z 34), Powerlink (Endolo-
gix, Irvine, CA, USA; n Z 3) and Aorfix (Lombard Medical
Technologies, Oxfordshire, UK: n Z 2). Percutaneous
access was used in 69 access vessels (16%). Additional
procedure-specific data are presented in Table 3. A cell
saver is routinely used during all EVAR procedures. This
reflects the history of increased blood loss with early
devices and sheath that had suboptimal haemostasis and
can likely be eliminated based on newer technology.
Anaesthetic management (LA with monitored
anaesthesia care)
All preoperative medication (including acetylsalicylic acid
and clopidogrel) was continued. Oral anticoagulation with
warfarin was stopped, and patients received low-
molecular-weight heparin. Patients had a preoperative
fasting period of 8 h. Premedication with 1e2 mg mid-
azolam, an H2 blocker, and glycopyrrolate was adminis-
tered. A radial arterial line, two 18G peripheral venous
catheter and a urinary Foley catheter were placed.
Routinely, no central venous catheter was used. PatientsTable 3 Procedure-specific data.
LA (n Z 183)
Access
- Cutdown 304 (83)
- Percutaneous 62 (17)
Operation time (min) 146 (60e465)
Fluroscopic time (min) 23 (9.7e78)
Contrast volume (ml) 165 (40e465)
Fluid administration
- Cristalloids (ml) 1500 (150e5000)
- Colloids
n (%) 10 (5)
ml 500 (100e800)
- Blood products
n (%) 16 (9)
ml 350 (250e2450)
- Cell saver
n (%) 71 (39)
ml 250 (160e2230)
LA: Local anesthesia, RA: Regional anesthesia, GA: General anesthesireceived a single dose of cephazolin antibiotic. Intra-
operative monitoring included continuous electrocardio-
gram (ECG), invasive arterial blood pressure, trans-
cutaneous oxygen saturation and urine output. A warming
mattress was used. Oxygen was supplied by nasal cannula
or mask, if necessary. A restrictive fluid-management
concept (1000e1500 ml crystalloids per procedure) was
applied. LA was achieved using infiltration of the access
sites (lidocaine 2%). For intravenous sedation, propofol was
used. Clinical end point of the sedation titration was the
minimal amount of propofol that created a still operation
field but maintained the airway. If necessary, a fentanyl
bolus (50e150 mg IV) for pain treatment was given.
Definitions and statistical analysis
Technical success was defined according to the reporting
standards for endovascular aortic aneurysm repair.14
Endoleaks were categorised as described by White et al.15
Pulmonary complications were defined as pneumonia,
required pharmacological or ventilator support. Renal
failure was defined as required temporary or permanent
dialysis.16 A retrospective analysis was performed. Institu-
tional Review Board approval for a retrospective review of
the study patients was obtained. Patients were analysed on
an intention-to-treat basis. Due to an inherited selection
bias of our approach, we report this study as an observa-
tional study, focussing on the results of patients undergoing
EVAR with LA. Data are expressed as median (range).
Results
Anaesthetic conversion from LA to GA was necessary in 14
patients (7.6%). Airway obstruction (n Z 4) and persistent
coughing (n Z 3) were the most common causes for
conversion to GA (Table 4). Two of four patients with airway
obstructions suffered from previous sleep apnoea. In allRA (n Z 9) GA (n Z 25)
9 (100) 43 (86)
e 7 (14)
131 (85e490) 143 (95e249)
19.8 (14.2e102) 23 (11e50.7)
103 (80e160) 175 (70e345)
1500 (600e4300) 1800 (100e2600)
1 (11) 2 (8)
1000 100/500
2 (22) 4 (16)
350/500 350 (250e860)
3 (33) 9 (36)
235 (150e1050) 250 (150e490)
a.
Table 4 Reasons for conversion from local to general
anesthesia (n Z 14).
Reason n (%)
Surgical conversion 2 (14)
Patient anxiety 3 (21)
Patient discomfort 1 (7)
Persistent coughing 3 (21)
Airway obstruction 4 (29)
Persistent patient movement 1 (7)
470 P. Geisbu¨sch et al.patients with airway-related complications, it was initially
tried to lighten the sedation and thus avoid conversion to
GA. Patient discomfort (n Z 1), anxiety (n Z 3) and
persistent patient movement (n Z 1) preventing exact
endograft placement were additional reasons for anaes-
thesiological conversion. Emergency surgical conversion to
open repair was required in two patients (0.9%) due to
accidental coverage of the renal arteries (and an additional
type I endoleak in one patient), which could not be resolved
by endovascular means. Both patients died during the
postoperative course (postoperative day 1 and 4) ofmulti-
organ failure.
Mortality
The overall 30-day mortality rate was 2.7%, with the five
deaths occurring in the LA group. All five patients (median
age 85 years) were scored ASA III (n Z 2) or IV (n Z 3) and
considered at high cardiac (n Z 3), pulmonary (n Z 3) and
renal (nZ 1) risk. Causes of death were multi-organ failure
(n Z 2, described above) and influenza-associated pneu-
monia (one patient with severe pre-existing chronicTable 5 Clinical outcomes.
LA (n Z 183)
30-day mortality 5 (2.7)
Perioperative morbidity 16 (8.7)
Cardiac complications 2 (1)
Respiratory complications 4 (2)
Renal complications 7 (3.8)
Access complications 3 (1.6)
Urin retention 2 (1)
Spinal cord ischaemia 1 (0.5)
MOV 2 (1)
Surgical conversion 2 (1)
Primary Endoleak
-Unkown type 1 (0.5)
-Type I 5 (2.7)
-Type II 39 (21)
-Type III 1 (0.5)
-Type IV 12 (6)
ICU stay
- n (%) 5 (2.7)
- days 3 (1e4)
Hospital stay (days) 2 (1e16)
LA: Local anesthesia, RA: Regional anesthesia, GA: General anesthesobstructive pulmonary disease (COPD) requiring constant
oxygen therapy). One patient died on the first post-
operative day of an unknown cause (autopsy denied by the
relatives), but a myocardial infarction was suspected.
Intra-operatively, an endoleak of unknown origin (but
highly suspicious for a type II) was noticed. The last patient
died on the 24th postoperative day of an unknown cause.
The operative and postoperative course was uneventful
(discharged on day 6).
A total of 23 of 217 patients (10.5%) experienced post-
operative complications. The complications of all patients
are shown in Table 5. The following paragraph describes the
16 of 183 (8.7%) patients with complications in the LA
group:Systemic complications
Cardiac complications were observed in two patients
(myocardial infarction and new onset of atrial fibrillation).
Pulmonary complications (nZ 4) included decompensation
of a pre-existing COPD requiring oxygen therapy on
discharge in two patients, pneumonia and pleural effusion
(requiring thoracenteses). Renal complications (n Z 7)
included contrast-induced acute or chronic renal failure in
three patients and partial embolic renal infarction in one
patient. In three of 183 patients (1.6%), accidental
coverage of renal arteries occurred and 2 of these 3
patients died post surgical conversion. In one of these 3
patients, the renal arteries were covered by a proximal
extension cuff placed for a type I endoleak. In the second
patient, proximal migration of the aortic cuff of a Power-
link endograft occurred during endorepair of an endoleak
type III. In both patients, repeated attempts to cannulate
the renal arteries or pull down the cuff with an inflatedRA (n Z 9) GA (n Z 25)
e e
1 (11) 5 (20)
e 2 (8)
e 1 (4)
e 1 (4)
1 (11) e
e 1 (4)
e e
e e
e e
e 1 (4)
e e
1 (11) 4 (16)
e e
e 3 (12)
1 (11) 3 (12)
1 1 (1e1)
3 (2e32) 2 (1e10)
ia MOV: multi-organ failure; ICU: intensive care unit.
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sion. In the third patient, a proximal extension cuff, placed
for an endoleak type I, partially covered one renal artery.
Catheterisation of the renal artery (including by trans-
brachial access) failed, and the patient was not considered
a candidate for open surgery but did not require dialysis. In
retrospect, it could not be evaluated whether these
complications were related to patient (e.g., respiratory
movements) or technical factors.
Non-systemic complications
Access-related complications were observed in three
patients (one groin haematoma and two postoperative
occlusion of the access vessel). One patient (no previous
aortic surgery, both hypogastric arteries patent) experi-
enced postoperative spinal cord ischaemia (bilateral, new
lower-extremity weakness and inability to void), which
resolved after spinal-fluid drainage.
Endoleaks
A type I endoleak was observed in five patients (2.7%). All
type I endoleaks were observed in the LA group in patients
with challenging aneurysm morphologies, including short
(<10 mm) landing zones (n Z 3) or angulated (>90) necks
(n Z 2). Treatment included emergency conversion in one
patient (described above). Two small type I endoleaks
resolved after 30 days. The other two patients with a type I
endoleak are lost to imaging follow-up but currently alive.
Intra-operatively, a type III endoleak was seen in one
patient. During endorepair, a proximal migration of the
stent graft resulting in renal artery coverage occurred and
emergency conversion was performed (see above).
Postoperative management
Postoperative painmanagement (Table 6) in patients with LA
required the use of opioids (74%), paracetamol (23%) and/or
a non-steroidal anti-inflammatory drug (3%). Intensive care
unit (ICU) stay was necessary in five of 183 (2.7%) patients,
which included two patients after emergency conversion,
1-day surveillance of two high-risk cardiac patients and the
patient with spinal cord ischaemia.
Discussion
The present series shows, that a ‘local anaesthesia first
strategy’ can be applied in 85% of the patients undergoing
EVAR. It was associated with a relevant anaesthetic
conversion (7.6%) and type I endoleak rate (2.7%), leavingTable 6 Postoperative pain managment.
LA (n Z 183)
Opioide 133 (73)
Paracetamol 43 (23)
NSAID 6 (3)
LA: Local anesthesia, RA: Regional anesthesia, GA: General anesthesiapproximately 75% of the patients in whom LA can
successfully be completed. Consistent with our series,
mortality rates after EVAR are reported between 1.2% and
3.7%, and a meta analysis has proven GA as a risk factor
(odds ratio (OR) 5.1 95% confidence interval (CI) 1.9e13.3)
for death after EVAR.7,17e19 However, even the few avail-
able larger studies that compare LA and RA/GA for EVAR
demonstrated no benefit from LA with regard to perioper-
ative mortality (Table 7), which might be caused by the low
mortality rates of current EVAR practice. This requires large
patient cohorts to demonstrate a possible effect of LA on
perioperative mortality.7,16
Regarding perioperative morbidity, different results are
reported and summarised in Table 7. While Verhoeven et al.
and the European Collaborators on Stent/Graft Techniques
for Aortic Aneurysm Repair (EUROSTAR) Registry report
a reduced (especially cardiac related) morbidity for LA,
other studies could not demonstrate this effect.5,16,20
However, the study from Verhoeven et al. and the EURO-
STAR data overlap a large proportion of patients (177 out of
310 in the LA group), which might explain similar results.
Anaesthetic conversion rates from LA to GA vary from 1% to
33% and seem to be lower in centres with more experience
in the application of LA.9,16,21,22 Verhoeven et al. report the
lowest anaesthesiological conversion rate of 1%, which
compares favourably with our rate of 7.6%. This might be
explained by their more rigid contraindications for LA (e.g.,
body mass index (BMI) > 30), which left 71% of all patients
eligible for LA in their series. In our series, LA was applied
to 84% of patients and could be completed in 76.4%. A
concern of LA is the issue of airway security, especially
when sedation is applied. This resulted in anaesthetic
conversion in four of 14 patients. Further reasons for
conversion included patient movements caused by
discomfort or persistent coughing. In addition, many
patients were not capable of holding their breath for
a prolonged time period. All these factors affect imaging
quality in LA and thus precise endograft placement. All type
I endoleaks occurred in the LA group in patients with
challenging aneurysm morphologies. The use of LA may
have meant that we were less able to obtain high-quality
imaging to get the optimal proximal seal and, given this
experience, we consider extremely challenging anatomies
as an additional relative contraindication for LA at present.
Our anaesthesiological strategy resulted in a restrictive
fluid management, which might be explained by a high
awareness for fluid management caused by the broad
application of LA and a low anaesthetic-induced vasodila-
tation. This series showed a short hospital stay (median 2
days), not only for LA patients, which might reflect rather
health-care-related issues than patient-/anaesthesia-
related causes, in our opinion. Other series have reportedRA (n Z 9) GA (n Z 25)
8 (89) 21 (84)
e 7 (28)
2 (22) 2 (8)
a NSAID: non-steroidal anti-inflammatory drug.
Table 7 Outcome of selected larger studies reporting on the use of local anesthesia for EVAR.
Study Patients LA/
Total
Conversion
LA to GA
Mortality
for LA
Type I endoleak
for LA
Morbidity for LA Comment
Verhoeven et al.16 170/239 (71%) 1% 0% n.r. 11.7% LA showed significantly
reduced systemic
complications compared
to GA
Ruppert et al.7
EUROSTAR data
310a/5557 (6%) n.r. 1.9% 2.6% 6.6% systemic
complications
4.6% access/
lower limb
complications
LA showed significantly
reduced systemic
complications compared
to GAa
De Virgilio et al.20 71/229 (31%) 13% 2.8% n.r. 19% No significant
differences in
cardiopulmonary
morbidity and mortality
between LA and GA
Bettex et al.21 63/91 (69%) 8% 0% n.r. Systemic
complications: 0%
Parra et al.3
Phase II
AneuRx Trial
50/429 (12%) n.r. 0% 0% 12%
Present study 183/217 (84%) 7.6% 2.7% 2.7% 8.7% Observational study
n.r.: not reported; LA: local anesthesia; GA: general anesthesia.
a 177/310 patients in the LA group of the EUROSTAR data were included by the center of Verhoeven et al.
472 P. Geisbu¨sch et al.a significant shortened overall hospital stay (mean 4e6 days
in European series) for LA patients.5,16 This study cannot
provide a cost analysis comparing LA and RA/GA in EVAR.
The aforementioned advantages of LA with respect to
morbidity, ICU and hospital stay might result in lower costs
of LA. However, at present, the discharge time after EVAR
is decreasing, and routine ICU stay for EVAR patients has
been abandoned in many centres, which might influence
costs’ analysis. The combination of LA with a percutaneous
access seems the next logical step towards an even more
minimally invasive treatment.23 We applied this combina-
tion in only 16% of all access vessels but are expanding the
use of percutaneous EVAR.
Conclusions
A ‘local anaesthesia first’ strategy can successfully be
applied in 75% of patients undergoing EVAR. The use of LA
can impact imaging quality and thus precise endograft
placement, which should be considered in patients with
challenging aneurysm morphologies.
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